Fresenius Group Overview

Investors

Fresenius Investment Highlights

  • Diversified revenue and earnings base with four strong business segments

  • Leading positions in non-cyclical markets with predictable growth

  • Industry-leading organic growth in all business segments

  • Strong earnings performance and cash flow generation

  • Attractive shareholder returns

  • Prudent financial management

"Our business results reflect our successful work for people. Record sales and earnings in 2017, along with the company’s strong guidance for this year and through 2020, show that our uncompromising focus on patients and quality also pays for our investors."
(Stephan Sturm, Chairman of the Management Board)

News

  • Fresenius terminates merger agreement with Akorn

    Fresenius has decided today to terminate the company’s merger agreement with Akorn, due to Akorn’s failure to fulfill several closing conditions. Fresenius’ decision is based on, among other factors, material breaches of FDA data integrity requirements relating to Akorn’s operations found during Fresenius’ ...

    April 22, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi launches IV Cancer Drug in the U.S.

    Melphalan Hydrochloride for Injection is the newest addition to the company’s oncology portfolio.

    April 16, 2018Fresenius Kabi
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Palonosetron Hydrochloride Injection is the newest addition to the company’s expanding portfolio of IV drugs. It is an antiemetic that can be used for chemotherapy-induced nausea and vomiting.

    April 11, 2018Fresenius Kabi
  • Brief News
    Fresenius Helios opens new ICU in Tenerife

    Quirónsalud Tenerife Hospital has opened a new intensive care unit, equipped with the latest medical equipment for treating as many as six critically ill patients at a time. Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, invested more than €1 million in the 400-square-meter (4,300-square-foot) ICU.

    April 06, 2018Fresenius Helios
    Fresenius reports 14th consecutive record year, aims at strong growth in 2018 and confirms mid-term growth targets
    February 26, 2018Fresenius
  • Brief News
    Fresenius Helios expands two hospitals in Germany

    Fresenius Helios recently opened a 130-bed building at the company’s hospital in Dachau, a city near Munich. The new structure is part of a €55 million renovation and expansion program that will include a modernization of the existing hospital building over the next two years. Meanwhile, in the northern German city of Nienburg/Weser, work has started on a building that will almost double the size of the emergency department at Fresenius Hospital Mittelweser. About €2.3 million is being invested in this project, which is scheduled for completion in the autumn.

    February 20, 2018Fresenius Helios
    Brief News
    Fresenius Helios presents inaugural science prize

    Fresenius Helios has presented the new Helios Science Prize for outstanding research by employees that contributes to improved treatment quality. The three winners all work at hospitals in Germany and were honored for their work in different areas of medicine. The prize, which comes with a cash award, went to Dr. Jitka Veldema of Helios Hospital Kipfenberg (for her work on stroke rehabilitation), Prof. Dr. Alexander Kreuter of Helios St. Elisabeth Hospital in Oberhausen (cancer diagnosis in HIV patients), and Dr. Patrick Weil of Helios University Hospital in Wuppertal (testicular cancer therapy).

    February 02, 2018Fresenius Helios
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Remifentanil is the newest addition to the company’s extensive portfolio of anesthesia and analgesia products. Remifentanil is a controlled substance sold only to licensed health care professionals for patient care and is distributed under strict controls in compliance with FDA and DEA regulations.

    January 29, 2018Fresenius Kabi
    Brief News
    S&P lifts Fresenius' rating outlook to positive

    Standard & Poor’s has revised Fresenius’ corporate credit outlook to positive from stable in late December 2017. The corporate credit rating was affirmed. Hence, Fresenius is now rated BBB- with positive outlook by Standard & Poor’s. Fresenius is rated investment grade by all of the three leading rating agencies Standard & Poor’s, Moody's and Fitch.

    January 19, 2018Fresenius
  • Brief News
    Fresenius Vamed wins awards for spa and wellness facilities

    VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2017” at the World Spa Awards. Three VAMED Vitality World facilities – St. Martins Thermal Spa & Lodge and Thermal Spa Laa Hotel & Spa, both in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.

    January 16, 2018Fresenius Vamed
    Brief News
    Fresenius Kabi launches IV Cancer Drug in the U.S.

    Bortezomib for intravenous use is the first and only available alternative to Bortezomib for Injection and is the newest addition to the company’s expanding oncology portfolio. 

    January 04, 2018Fresenius Kabi
  • Fresenius expects meaningful positive effects from US tax reform
    December 22, 2017Fresenius
    Brief News
    Fresenius Helios builds new hospital in Spain

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, will build a hospital in the city of Alcalá de Henares, just outside of Madrid. The approximately 11,000-square-meter (118,000-square-foot) facility will include 106 beds, four operating rooms and two delivery rooms. Quirónsalud will invest about €27 million in the new hospital. It is scheduled to open in 2019.

    December 20, 2017Fresenius Helios
  • Brief News
    Fresenius submits first biosimilar Marketing Authorization Application

    Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.

    December 18, 2017Fresenius Kabi
    Brief News
    Fresenius Kabi opens production facility in Indonesia

    Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.

    November 24, 2017Fresenius Kabi
  • Brief News
    Fresenius Vamed acquires third Swiss rehabilitation clinic

    Fresenius Vamed has acquired a rehabilitation clinic in Switzerland, its third in the country. The clinic in Seewis has about 75 beds and specializes in heart disease, internal medicine and psychosomatic illnesses. Fresenius Vamed is now active in all major areas of rehabilitative medicine in Switzerland, with a clinic in Zihlschlacht that specializes in neurology and one in Dussnang specializing in orthopedics and geriatrics.

    November 08, 2017Fresenius Vamed
    Fresenius reports another strong quarter and confirms guidance
    November 02, 2017Fresenius
  • Brief News
    Fresenius Vamed opens Institute for Gender Medicine

    Fresenius Vamed has opened the Institute for Gender Medicine in cooperation with the Medical University of Vienna. This new research institute, in the Lower Austria town of Gars am Kamp, will focus on the different needs of female and male patients, for example in the interpretation of disease symptoms. Fresenius Vamed will be able to use the institute’s research findings to develop tailored treatment offerings in areas such as prevention and rehabilitation. The Institute for Gender Medicine complements initiatives for individualized medical care already being carried out by the VAMED International Medical Board and its approximately 650 physicians.

    October 19, 2017Fresenius Vamed
    Brief News
    Fresenius Helios expands university hospital in Madrid

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is undertaking a major expansion of University Hospital Quirónsalud Madrid. A new, 6,000-square-meter (almost 65,000-square-foot) wing scheduled for completion by next summer will add 52 new beds, bringing the hospital’s total to 288. The expansion will also include 25 doctors’ offices, nine resuscitation rooms and three delivery rooms, as well as two hybrid operating rooms that can be used both for conventional operations and for minimally invasive surgical procedures – so-called “keyhole surgery.” All expansion and modernization measures should be completed by the end of 2018. The total investment is about €31 million.

    October 04, 2017Fresenius Helios
  • Brief News
    2018 DRG inflator for German hospitals set at 2.97%

    The price increase for hospital services in Germany has been set at 2.97% for 2018. This is in line with the level of past years.

    September 15, 2017Fresenius Helios
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Caspofungin, an antifungal medicine, expands the company's sterile injectable anti-infective portfolio.

    September 12, 2017Fresenius Kabi
  • Fresenius Kabi completes acquisition of Merck KGaA’s biosimilars business
    September 01, 2017Fresenius Kabi
    Brief News
    Fresenius refinances Credit Agreement successfully – S&P rates bonds now investment grade

    The amended 2013 Credit Agreement streamlines Fresenius’ financing structure by replacing the existing senior secured facilities with unsecured facilities. Concurrently, the guarantor structure was aligned, with Fresenius SE & Co KGaA now being sole guarantor. The Credit Agreement has an aggregate amount of approximately €3.8 billion and consists of revolving facilities and term loans with maturities in 2021 and 2022. The transaction was well received by investors and substantially oversubscribed. On the basis of the unsecured structure and consistent with the corporate credit rating of Fresenius, S&P has raised the rating of the Fresenius bonds to BBB- from BB+.

    August 24, 2017Fresenius
  • Brief News
    Fresenius Helios invests in German hospital network

    Fresenius Helios continues to invest in the expansion and modernization of its hospitals and clinics. HELIOS Clinic Geesthacht, located just east of Hamburg, has opened an extension with 20 additional neurological rehabilitation places for young people. The investment in the specialist clinic for neurology and neurological rehabilitation is €4.6 million. In the state of Saxony, meanwhile, work has started on a new building for the emergency ward at HELIOS Hospital Leisnig. This €3.3 million project is scheduled for completion in autumn 2018.

    August 22, 2017Fresenius Helios
    Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth
    August 01, 2017Fresenius
  • Fresenius appoints Rachel Empey as Chief Financial Officer
    July 21, 2017Fresenius
    Brief News
    Fresenius Helios expands hospital near Berlin

    Fresenius Helios is investing more than €18 million to expand the company’s hospital in the German town of Bad Saarow, about 25 kilometers (15 miles) east of Berlin. The project at HELIOS Hospital Bad Saarow includes construction of a new building that will add bed capacity to meet growing demand, and an expansion of the radiology department. The construction is scheduled for completion in spring 2019.

    July 20, 2017Fresenius Helios
  • Akorn shareholders approve merger agreement with Fresenius Kabi - Closing expected latest by early 2018
    July 20, 2017Fresenius Kabi
    Brief News
    Fresenius wins award for Quirónsalud acquisition

    Fresenius was presented yesterday with the Corporate Finance Award for the company's acquisition of Quirónsalud, Spain’s largest private hospital operator. The award is given annually by the major German business daily Börsen-Zeitung for transactions judged to be outstanding in both strategical and financial terms. Fresenius won in the Large Caps category, which groups major companies. With the Quirónsalud acquisition, the Börsen-Zeitung said, “Fresenius succeeded in making a quantum leap in the hospital business."

    June 23, 2017Fresenius
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Azacitidine, a nucleoside metabolic inhibitor, expands the company's sterile injectable portfolio in oncology.

    June 01, 2017Fresenius Kabi
Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

Please enter your first name.
Please enter your last name.
Please enter your company.
Please enter your department.
Please enter your function.
Please enter your street.
Please enter your postal code and city.
Please enter your e-mail address.

Please send me via email


Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470. 

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com


Contact
Visit us

Fresenius SE & Co. KGaA

Fresenius uses cookies on this website to enhance the user experience and provide the best possible service. By continuing to browse the website, you consent to our use of cookies.

Learn more
OK